News | 2/20/2024

Health Advances Promotes Rare Disease Expert Doug Mullen, PhD to Vice President

Boston, MA – December 21, 2023

Doug joined Health Advances in 2017 and co-leads both the rare disease practice and the biopharma transactions practice, supporting biopharma executive teams and biotech investor teams across the world. His work focuses on new product planning, commercial due diligence, and portfolio strategy. Doug also has deep expertise in quantitative analysis including product forecasting, P&L modeling and deal valuation, and real-world data studies. Prior to joining Health Advances, Doug worked in growth strategy consulting at Fletcher Spaght, Inc., and new venture creation at the University of Michigan Health System. He began his career as the Dick Sarns Medical Innovation Fellow at the University of Michigan Health System.

Doug holds a PhD and MSE in Macromolecular Science and Engineering from the University of Michigan. His graduate research in polymeric nanoparticle-based delivery for oncology and gene therapy resulted in 18 peer-reviewed articles. He also holds a BSE from Duke University.

“We are thrilled to promote Doug and recognize the impact he has made across numerous rare disease companies and investors,” said Sheela Hegde, Managing Partner and Global Head at Health Advances. “Doug brings both deep technical insight and strong business savvy to all his work, and is a true partner with all his clients. We are lucky to have him on our team!